Journal of Proteomics & Bioinformatics
Open Access
ISSN: 0974-276X
ISSN: 0974-276X
Yuri L Lyubchenko
University of Nebraska Medical Center, USA
Keynote: J Proteomics Bioinform
Statement of the Problem: The amyloid cascade hypothesis is currently considered as the main model for a vast number of neurodegenerative diseases including Alzheimer??s, Parkinson??s, and Huntington??s diseases. Numerous studies have shown that amyloidogenic proteins are capable of spontaneous assembly into aggregates, and eventually form fibrillar structures found in amyloid or amyloid?like deposits. However, there is a serious complication with translating current knowledge on amyloid aggregation in vitro to understand the aggregation process in vivo. If the critical concentration for the spontaneous aggregation of Aβ peptide in vitro is in the micromolar range, physiological concentrations of Aβ are in the low nanomolar range making impossible amyloids to assemble. Methodology & Theoretical Orientation: We discovered a novel on-surface aggregation pathway that allows for spontaneous assembly of amyloid beta peptides at the physiological concentration range. We combined experimental studies involving singlemolecule time-lapse AFM imaging with all-atom molecular dynamic simulations to characterize the on-surface self-assembly process of amyloid proteins. Experimental data demonstrate that on-surface aggregation occurs in the physiological range of concentrations of the proteins. Our combined experimental and computer modeling approaches demonstrate that the on-surface aggregation is a dynamic process, so the assembled aggregate can dissociate from the surface to the bulk solution. As a result, the dissociated oligomers can play roles of seeds for aggregation in the bulk solution or start a neurotoxic effect such as phosphorylation of the tau protein to initiate its misfolding and aggregation. Both processes can lead to neurodegeneration. Conclusion & Significance: We posit that on-surface aggregation is the mechanism by which neurotoxic amyloid aggregates are produced under physiological conditions. A change in membrane properties leading to an increase in affinity of amyloid proteins to the membrane surface facilitates the assembly of stable oligomers. The proposed model is a significant departure from the current model as it directs the development of treatments and preventions towards approaches that control the cell membranes composition to prevent the on-surface aggregation process. Recent Publications 1. Banerjee S, Hashemi M, Lv Z, Maity S, Rochet J C and Lyubchenko Y L (2017) A novel pathway for amyloids selfassembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. Scientific Reports 7:45592. 2. Banerjee S, Sun Z, Hayden E Y, Teplow D B and Lyubchenko Y L (2017) Nanoscale dynamics of amyloid beta-42 oligomers as revealed by high-speed atomic force microscopy. ACS Nano 11(12):12202-12209 3. Maity S, Hashemi M and Lyubchenko Y L (2017) Nano-assembly of amyloid beta peptide: role of the hairpin fold. Scientific Reports 7:2344. 4. Maity S, Viazovkina E, Gall A and Lyubchenko Y L (2017) Single-molecule probing of amyloid nano-ensembles using the polymer nanoarray approach. Physical Chemistry Chemical Physics 19:16387-16394. 5. Zhang Y, Hashemi M, Lv Z, Williams B, Popov K I, Dokholyan N V and Lyubchenko Y L (2018) High-speed atomic force microscopy reveals structural dynamics of alpha-synuclein monomers and dimers. The Journal of Chemical Physics 148:123322.
Yuri L Lyubchenko is a Professor of Pharmaceutical Sciences at the University of Nebraska Medical Center, USA. His research focuses on understanding fundamental mechanisms underlying health and disease, which is a key for developing new and more effective diagnostics and medications. This primary basic research allows him not only to identify new drug targets for small molecule drugs, it also leads to development of the nanotools and methods to discover novel approaches for diagnostic, treatment and disease prevention and to more rapidly determine their efficacy at the molecular level.